| 2018-10-12 09:05:17|
IRIX 09:05 10/12 10/12/18
IRIDEX transferred with a Buy at Roth Capital
Roth Capital transferred coverage of IRIDEX to analyst David Solomon, who maintains a Buy rating but lowered the price target on the stock to $10 from $11. G6 probes are forecasted to drive about 20% top-line growth from FY19-FY23, with gross margins forecasted to expand to 60-65% by FY23, which could drive substantial earnings growth, Solomon tells investors.